Search research articles
Contact Us
Filters
Showing results (231-240 of 270) with videos related to
Page
of 27
Sort By:
Nature Communications
|
October 31, 2020
SARS-CoV-2 viral load is associated with increased disease severity and mortality
Jesse Fajnzylber, James Regan, Kendyll Coxen, et al.
The Journal of Infectious Diseases
|
February 17, 2026
Impact of COVID-19 Monoclonal Antibody Therapy on Subsequent Vaccine-elicited SARS-CoV-2 Immune Responses
Davey Smith, Isabelle R Weir, Sydney Ramirez, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 29, 2024
2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis
Adarsh Bhimraj, Yngve Falck-Ytter, Arthur Y Kim, et al.
Annals of Internal Medicine
|
April 17, 2023
Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19
Teresa H Evering, Kara W Chew, Mark J Giganti, et al.
Science Translational Medicine
|
October 19, 2021
Maternal SARS-CoV-2 infection elicits sexually dimorphic placental immune responses
Evan A Bordt, Lydia L Shook, Caroline Atyeo, et al.
Open Forum Infectious Diseases
|
September 22, 2025
Rapid Elimination of Culturable SARS-CoV-2 With Intramuscular or Intravenous Administration of Antiviral Monoclonal Antibody Therapy
Rinki Deo, Manish C Choudhary, Owen T Glover, et al.
JAMA Network Open
|
September 25, 2024
Emerging SARS-CoV-2 Resistance After Antiviral Treatment
Trevor J Tamura, Manish C Choudhary, Rinki Deo, et al.
Medrxiv : the Preprint Server for Health Sciences
|
March 9, 2022
Vaccine Breakthrough Infection with the SARS-CoV-2 Delta or Omicron (BA.1) Variant Leads to Distinct Profiles of Neutralizing Antibody Responses
Michael S Seaman, Mark J Siedner, Julie Boucau, et al.
Medrxiv : the Preprint Server for Health Sciences
|
September 21, 2021
Emergence of SARS-CoV-2 Resistance with Monoclonal Antibody Therapy
Manish C Choudhary, Kara W Chew, Rinki Deo, et al.
JCI Insight
|
October 10, 2022
Vaccine breakthrough infection leads to distinct profiles of neutralizing antibody responses by SARS-CoV-2 variant
Michael S Seaman, Mark J Siedner, Julie Boucau, et al.
Page
of 27
Search research articles
Search
Showing results (231-240 of 270) with videos related to
Sort By:
Page
of 27
Nature Communications
|
October 31, 2020
SARS-CoV-2 viral load is associated with increased disease severity and mortality
Jesse Fajnzylber, James Regan, Kendyll Coxen, et al.
The Journal of Infectious Diseases
|
February 17, 2026
Impact of COVID-19 Monoclonal Antibody Therapy on Subsequent Vaccine-elicited SARS-CoV-2 Immune Responses
Davey Smith, Isabelle R Weir, Sydney Ramirez, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 29, 2024
2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis
Adarsh Bhimraj, Yngve Falck-Ytter, Arthur Y Kim, et al.
Annals of Internal Medicine
|
April 17, 2023
Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19
Teresa H Evering, Kara W Chew, Mark J Giganti, et al.
Science Translational Medicine
|
October 19, 2021
Maternal SARS-CoV-2 infection elicits sexually dimorphic placental immune responses
Evan A Bordt, Lydia L Shook, Caroline Atyeo, et al.
Open Forum Infectious Diseases
|
September 22, 2025
Rapid Elimination of Culturable SARS-CoV-2 With Intramuscular or Intravenous Administration of Antiviral Monoclonal Antibody Therapy
Rinki Deo, Manish C Choudhary, Owen T Glover, et al.
JAMA Network Open
|
September 25, 2024
Emerging SARS-CoV-2 Resistance After Antiviral Treatment
Trevor J Tamura, Manish C Choudhary, Rinki Deo, et al.
Medrxiv : the Preprint Server for Health Sciences
|
March 9, 2022
Vaccine Breakthrough Infection with the SARS-CoV-2 Delta or Omicron (BA.1) Variant Leads to Distinct Profiles of Neutralizing Antibody Responses
Michael S Seaman, Mark J Siedner, Julie Boucau, et al.
Medrxiv : the Preprint Server for Health Sciences
|
September 21, 2021
Emergence of SARS-CoV-2 Resistance with Monoclonal Antibody Therapy
Manish C Choudhary, Kara W Chew, Rinki Deo, et al.
JCI Insight
|
October 10, 2022
Vaccine breakthrough infection leads to distinct profiles of neutralizing antibody responses by SARS-CoV-2 variant
Michael S Seaman, Mark J Siedner, Julie Boucau, et al.
Page
of 27